Skip to content 
OUR MAMS PLATFORM TRIALS
SLEIPNIR is a pioneering platform designed to test multiple compounds for target engagement in parallel, advancing only the most promising candidates to HYDRA.
HYDRA is a phase III trial platform that will investigate whether candidate treatments that pass testing at SLEIPNIR can slow or stop the progression of Parkinson’s disease.
WHAT ARE MULTI-ARM MULTI-STAGE (MAMS) PLATFORM TRIALS?
MAMS is a flexible and adaptative design that answers multiple research questions simultaneously, by allowing several treatments to be tested at the same time against a single placebo group. Promising therapies can move forward, while those that show little or no benefit are stopped early. New treatments can also be added along the way. After a short wash-out period—time needed to clear the effects of a previous treatment—participants can switch into other study arms. This approach makes it possible to identify effective therapies more efficiently.
ADVANTAGES OF MAMS STUDIES
FLEXIBILITY
Multiple treatments tested simultaneously, allowing early detection of the most promising arms.
ANSWER MULTI QUESTIONS
Answer multi questions under a single trial and regulatory framework, rather than answering them separately in different trials, as in traditional designs.
BETTER ALLOCATION OF PATIENTS
One placebo group and several treatment arms, maximises the number of participants on treatment.
FASTER AND LESS COSTLY
With no need to set up an entire new clinical trial for each new intervention, MAMS trials are faster and less costly.
